Calistoga Pharmaceuticals Announces Initiation of Phase 2 Trial of Delta-Isoform-Selective PI3 Kinase Inhibitor CAL-101 in Combination with Rituximab for the Treatment of Previously Untreated Elderly Patients with Chronic Ly